Latanost Eye Drops 0.005%

País: Malasia

Idioma: inglés

Fuente: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Ingredientes activos:

Latanoprost

Disponible desde:

DUOPHARMA (M) SDN. BHD.

Designación común internacional (DCI):

Latanoprost

Unidades en paquete:

2.5 ml

Fabricado por:

DUOPHARMA (M) SDN. BHD.

Información para el usuario

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
1
LATANOST EYE DROPS 0.005%
Latanoprost 0.005%
WHAT IS IN THE LEAFLET
1.
What
LATANOST
is used for
2.
How
LATANOST
works
3.
Before you use
LATANOST
4.
How to use
LATANOST
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
LATANOST
8.
Product Description
9.
Manufacturer
10.
Product Registration Holder
11.
Date of Revision
WHAT LATANOST IS USED FOR
LATANOST
is
used
to
treat
eye
conditions that are linked to an increase
in the pressure within the eye (open
angle glaucoma, chronic angle closure
glaucoma and ocular hypertension) in
adult, that can eventually affect your
eyesight.
LATANOST
is
also
used
to
treat
increased eye pressure and glaucoma in
children
HOW LATANOST WORKS
LATANOST
contains
Latanoprost
which
is
belongs
to
a
group
of
medicines
known
as
prostaglandin
analogues.
LATANOST works by increasing the
natural outflow of fluid from inside the
eye
into
the
bloodstream
and
thus
reducing the eye pressure.
BEFORE YOU USE LATANOST
-
_When you must not take it_
_ _
Do not start using LATANOST if you or
your child is allergic (hypersensitive) to
latanoprost or any of the
other ingredients of LATANOST
If you are not sure whether you should start
taking this medicine, talk to your doctor or
pharmacist.
_Pregnancy and lactation _
Tell your doctor immediately if you are
pregnant, think you are pregnant, or are
planning to become pregnant. Your doctor
will discuss the possible risks and benefits
of using LATANOST during pregnancy.
LATANOST should be used with caution
if you are breastfeeding. Ask your doctor
or
pharmacist
for
advice
before
using
LATANOST if you are breastfeeding.
-
_Before you start to use it _
Check
with
your
doctor
or
pharmacist
before using LATANOST if you think any
of the following applies to you. The same
applies if your child has been prescribed
LATANOST.
-
If you or your child suffer from eye
problem (such as absence of the lens
in the eye, or presence of artificial
lens)
-
If
you
or
your child
have
severe
asthma or if the asthma

Ficha técnica

[DUOPHARMA (M) SDN BHD]
Page 1 of 3
Revision Date: 06.07.2020
LATANOST EYE DROPS 0.005%
DESCRIPTION:
LATANOST EYE DROPS 0.005%: A clear, colourless solution.
COMPOSITION:
Each 1 ml contains 50 mcg of latanoprost. Contains preservative:
benzalkonium chloride 0.2 mg/ml.
PHARMACODYNAMICS:
Pharmacotherapeutic group: Ophthalmologicals; Antiglaucoma
preparations and miotics, prostaglandin analogues. ATC code: S 01 E E
01
The active substance latanoprost, a prostaglandin F2α analogue, is a
selective prostanoid FP receptor agonist which reduces the IOP by
increasing the outflow of aqueous humour. Reduction
of the IOP in man starts about three to four hours after
administration and maximum effect is reached after eight to twelve
hours. Pressure reduction is maintained for at least 24 hours.
Studies indicated that the main mechanism of action is increased
uveoscleral outflow, although some increase in outflow facility
(decrease in outflow resistance) has been reported in man.
PHARMACOKINETICS:
Absorption
Latanoprost (mw 432.58) is an isopropyl ester prodrug which per se is
inactive, but after hydrolysis to the acid of latanoprost becomes
biologically active.
The prodrug is well absorbed through the cornea and all drug that
enters the aqueous humour is hydrolysed during the passage through the
cornea.
Distribution
The peak concentration in the aqueous humour is reached about two
hours after topical administration.
Biotransformation and elimination
There is practically no metabolism of the acid of latanoprost in the
eye. The main metabolism occurs in the liver. The half-life in plasma
is 17 minutes in man. The main metabolites, the 1,2-
dinor and 1,2,3,4-tetranor metabolites, exert no or only weak
biological activity in animal studies and are excreted primarily in
the urine.
INDICATIONS:
▪
Reduction of elevated intraocular pressure (IOP) in patients with
open-angle glaucoma, chronic angle closure glaucoma and ocular
hypertension
▪
Reduction of elevated intraocular pressure in paediatric patients with
elevated intraocula